EB-DT-NK-UC101

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameEB-DT-NK-UC101
Drug Alias NameAllogeneic cord-blood-derived dual-target Nectin-4/HER2 CAR-NK cells therapy (Beijing Biotech)EB-DT-NK-UC101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNatural killer cell replacementsNectin-4 modulatorsReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2Nectin-4
Therapy Area/IndicationsUrinary Bladder NeoplasmsUrethral NeoplasmsCarcinoma, Transitional Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Biotech
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsUrethral NeoplasmsCarcinoma, Transitional Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A